F-1/A: ANEW HEALTH IPO: Hong Kong Pain Management Firm Seeks Nasdaq Listing

ANEW HEALTH LIMITED, a Hong Kong-based pain management and health services provider, is seeking to raise up to $7.2 million in an initial public offering on the Nasdaq Capital Market, despite a significant decrease in net income and a going concern warning from its auditor.

Summary

• ANEW HEALTH LIMITED is conducting an Initial Public Offering (IPO) of 1,800,000 Ordinary Shares on the Nasdaq Capital Market under the symbol AVG, with an expected price range of US$4.00 to US$6.00 per share.
• The company, established in 2007, is a Hong Kong-based pain management and health services provider operating under the ANKH brand, offering non-surgical, non-invasive, and non-pharmacological treatments, as well as topical and dietary supplements.
• Its core approach, RDS+ (Restore, Detox, and Strengthen), combines Traditional Chinese Medicine (TCM) wisdom with energy-based treatment devices.
• The company served 10,039 clients in FY2025 and 8,692 in FY2024, with average annual client spending increasing by approximately 3.2% to US$6,478 in FY2025.
• Total revenue slightly decreased by 1.9% from US$40.8 million in FY2024 to US$40.0 million in FY2025.
• Net income experienced a significant 53% decrease, falling from US$11.7 million in FY2024 to US$5.5 million in FY2025, primarily due to increased cost of revenue, marketing, and general and administrative expenses.
• The company's auditor expressed "substantial doubt" about its ability to continue as a going concern, citing working capital deficits of US$7,827,815 in FY2025 and US$7,765,739 in FY2024.
• Post-IPO, AW Ocean Limited, the controlling shareholder, will retain 96.53% of the total voting power, classifying the company as a controlled company under Nasdaq rules.

Sentiment

Score: 3

Explanation: The company is pursuing an IPO and operates in a growing market with a recognized brand and clear expansion strategies. However, the significant decline in net income (53%), persistent working capital deficit, and the auditor's 'going concern' warning indicate substantial financial instability and high operational risks. The high concentration of ownership and potential for stock price volatility further add to the risk profile, outweighing the positive market trends and strategic plans.

Positives

• The ANKH brand is well-recognized and trusted in Hong Kong, with over 16 years of experience in pain management and functional enhancement.
• The RDS+ approach, combining Traditional Chinese Medicine and advanced energy-based devices, offers non-surgical, non-invasive, and non-pharmacological treatments.
• Internal customer surveys show high satisfaction rates: 81.7% overall service satisfaction, 87.8% satisfaction with therapist treatment, and 69.4% reported pain reduction.
• The company offers a broad range of treatment procedures utilizing 371 energy-based treatment devices sourced internationally, carrying certifications like CE, ISO, or GMP.
• The senior management team consists of dedicated industry veterans with extensive experience in the health and wellness sector.
• Rigorous service standards, well-established quality control, and comprehensive training systems contribute to high customer satisfaction and low refund rates (0.86% of contracted sales in FY2025).
• The non-pharmacological pain management market in Hong Kong is growing, driven by an aging population, increasing health awareness, and demand for post-COVID-19 condition relief.
• The company plans to expand its customer base and service center network in Hong Kong and strategically into selected global markets (Singapore, Malaysia, Japan, South Korea, Canada, and the United States).
• Plans include enhancing research and development capabilities to introduce portable energy-based at-home treatment devices.
• The company's auditor, WWC, P.C., is headquartered in California and subject to PCAOB inspections, not affected by the 2021 PCAOB determination regarding China/Hong Kong firms.

Negatives

• The company's auditor expressed "substantial doubt" about its ability to continue as a going concern due to working capital deficits of US$7,827,815 in FY2025 and US$7,765,739 in FY2024.
• Net income decreased significantly by 53% from US$11.7 million in FY2024 to US$5.5 million in FY2025.
• Total revenue slightly decreased by 1.9% from US$40.8 million in FY2024 to US$40.0 million in FY2025.
• Cost of revenue increased by 16.8% (US$1.9 million) in FY2025, primarily due to higher personnel costs from an increased headcount (from 55 to 74 operation and support personnel).
• General and administrative expenses rose by 46.8% (US$3.6 million) in FY2025, driven by increased senior management compensation, a one-off discretionary bonus of US$1.28 million, and costs associated with opening a new treatment center.
• The company relies on a single geographical market (Hong Kong), making it vulnerable to adverse economic, social, and political conditions in the region.
• Management team lacks experience in managing a U.S. public company and complying with associated regulatory requirements.
• No long-term supply agreements exist with treatment device suppliers, posing risks of supply disruptions, cost increases, or quality deterioration.
• The company does not maintain product liability insurance, which could expose it to substantial financial and reputational damage from claims.
• The concentration of ownership, with AW Ocean Limited holding 96.53% of voting power post-IPO, means corporate actions will be substantially controlled by the controlling shareholder, potentially limiting protections for public shareholders.
• Reliance on dividends from Hong Kong subsidiaries to fund cash requirements, which could be restricted by future interventions from the PRC government.
• Significant uncertainties exist regarding the interpretation and enforcement of PRC laws and regulations in Hong Kong, potentially impacting operations or the value of Ordinary Shares.
• The Ordinary Shares may be thinly traded, making it difficult for investors to sell shares at or near ask prices, or at all.
• New investors in the offering will incur immediate and substantial dilution in the book value of their shares (approximately US$3.79 per share at the minimum offering price).

Risks

• The working capital deficit as of March 31, 2025 and 2024 raises substantial doubt about the company's ability to continue as a going concern.
• Significant variability in operating results due to increased operating expenses and cost of revenue could adversely affect profitability.
• Unfavorable publicity or consumer perception could negatively affect business performance and reputation.
• Exposure to customer complaints, claims, and legal proceedings in the regular course of operations.
• Failure to maintain the quality of equipment, treatment devices, supplies, topical use, and dietary supplement products could lead to liabilities and reputational damage.
• Reliance on third-party suppliers, including limited source suppliers, for products and certain treatment devices, could result in lost revenue if they fail to produce on time or to specifications.
• Absence of long-term supply agreements with treatment device suppliers could lead to decreased supply, increased costs, or quality deterioration.
• Inherent risks relating to product liability claims or product recalls, with no product liability insurance, could cause significant expenses and damages.
• Inability to hire and retain qualified personnel, especially consultants and therapists, could adversely affect service quality and business strategy.
• Intense competition in the pain management and health industry could lead to loss of market share and reduced profitability.
• If the market for products and services does not continue to grow, grows more slowly than expected, or fails to grow as large as expected, business, financial condition, and operating results may be adversely affected.
• Reliance on a single geographical market (Hong Kong) exposes the business to adverse economic, social, and/or political conditions.
• Introduction of disruptive technological breakthroughs (energy-based, pharmaceutical, or other) may present additional challenges.
• Newly opened and acquired service centers may not achieve anticipated operating results.
• Dependence on the continued services of certain key personnel; loss of whom could greatly harm business.
• Management team lacks experience in managing a U.S. public company and complying with applicable laws.
• Failure to effectively maintain, promote, and enhance the ANKH brand in a cost-effective manner could harm business and competitive advantage.
• Any substantial increase in rent or non-renewal of lease agreements may affect operations and financial condition.
• Cybersecurity risks, breaches, and other disruptions could compromise customer personal data and treatment records, damage reputation, and expose the company to liability.
• Occurrence of force majeure events, natural disasters, adverse weather, pandemic outbreaks, terrorist acts, and global political events could impair operations or cause customer traffic decline.
• Business involves significant risks and uncertainties that may not be covered by insurance.
• The PRC government may exercise significant direct oversight and discretion over Hong Kong operations, potentially resulting in a material change in operations and/or share value.
• Uncertainties exist regarding potential future requirements for approvals from PRC authorities to list on U.S. exchanges and offer securities, or compliance with data security laws.
• The enforcement of laws, rules, and regulations in the PRC and Hong Kong can change quickly with little advance notice, limiting legal protections.
• The enactment of the Hong Kong National Security Law could impact Hong Kong subsidiaries, which represent substantially all of the business.
• Political risks associated with conducting business in Hong Kong.
• Changes in currency conversion rates between Hong Kong dollar and U.S. dollar may affect the value of investments.
• Corporate actions will be substantially controlled by AW Ocean Limited, which will have the ability to control or exert significant influence over important corporate matters.
• Reliance on dividends and other distributions from subsidiaries to fund cash and financing requirements, which may be restricted by PRC government interventions.
• Enforcement of foreign civil liabilities in the Cayman Islands and Hong Kong is subject to certain conditions, making U.S. judgments difficult or impossible to enforce.
• Difficulties in protecting interests and limited ability to protect rights through U.S. courts due to Cayman Islands incorporation.
• Ordinary Shares may be prohibited from trading on a national exchange under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB is unable to inspect auditors for two consecutive years.
• No public market for Ordinary Shares prior to this offering, and no assurance of a liquid public market developing.
• Extreme stock price volatility unrelated to actual or expected operating performance, financial condition, or prospects.
• Ordinary Shares may be thinly traded, making it difficult to sell at or near ask prices or at all.
• Immediate and substantial dilution in the book value of shares for new investors.
• Sale or availability for sale of substantial amounts of Ordinary Shares in the public market could adversely affect the market price.
• If securities or industry analysts do not publish research or reports, or publish negative reports, the price and trading volume could decline.
• Broad discretion in the use of net proceeds from this offering, which may not be used effectively.
• Nasdaq may apply additional and more stringent criteria for initial and continued listing due to small public offering and large insider holdings.
• Failure to satisfy Nasdaq Capital Market listing requirements could lead to delisting.
• Reduced disclosure requirements as an emerging growth company may make Ordinary Shares less attractive to investors.
• Exemptions as a foreign private issuer may afford less protection to shareholders compared to U.S. domestic public companies.
• Potential loss of foreign private issuer status in the future could result in significant additional costs and expenses.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.
• Reliance on price appreciation of Ordinary Shares for investment return, as no dividends are planned in the foreseeable future.
• Risk of being classified as a Passive Foreign Investment Company (PFIC) for United States federal income tax purposes.

Future Outlook

The company plans to expand its customer base and service center network in Hong Kong, enhance brand awareness, and strategically expand into selected global markets such as Singapore, Malaysia, Japan, South Korea, Canada, and the United States. It also intends to substantially enhance research and development capabilities to develop and commercialize energy-based treatment devices for both professional use and a portable home-use consumer retail market, with prototypes expected in early 2026 and market readiness by the end of 2026.

Management Comments

• "We believe that our professional services, proven approach to pain management, and capability to offer a broad range of treatment services and products have enabled us to offer our clients distinguished experience at our service centers."
• "The ANKH brand has become a well-recognized, trustworthy, and reliable icon in Hong Kong for the provision of quality pain management and health services."
• "We believe that we have sufficient funds to meet our operating and capital expenditure needs and obligations in the next 12 months."

Industry Context

The non-pharmacological pain management market in Hong Kong is experiencing significant growth, driven by an aging population (projected to reach 2.52 million aged 65+ by 2039), increasing public awareness of health and pain management, and the rising prevalence of post-COVID-19 conditions (Long COVID). Consumers are increasingly seeking non-pharmaceutical options due to concerns about opioid addiction and side effects. The market is characterized by intense competition and fragmentation, with a shift towards more pain-focused models and multidisciplinary management. High entry barriers include capital intensity, the need for quality service and strong brand recognition, and a limited supply of experienced Chinese medicine practitioners and therapists.

Comparison to Industry Standards

• Ranked no.3 in terms of average spending per customer in the non-pharmacological pain management services market in Hong Kong.
• Ranked no. 4 in customer experience trails in the non-pharmacological pain management services market in Hong Kong.
• Premium pain management brands in Hong Kong target high-income consumers, who had an average spending of HK$49,124 in 2024, representing a CAGR of 20.1% from HK$34,074 in 2022.
• Competitors include NYMG Pain Center (25 branches, subsidiary of EC Healthcare), New Hope Medical (2 branches), Hong Kong Medical Pain Management Association (2 branches), and HK Pain Tech Institute (5 branches).

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the prospectus, the company has not been involved in any legal proceedings, investigations, or claims, nor is it aware of any pending or threatened litigation, arbitration, or other claims that would have a material adverse impact on its operations, financial position, and reputation.

Related Party Transactions

• On September 27, 2024, Anew Health declared a dividend of US$10,740,727 to AW Ocean Limited (the Controlling Shareholder) to partially set off amounts due from Mr. Ka Wai Victor, MO (Chief Executive Officer and Chairman of the Board).
• Amounts due from Mr. Ka Wai Victor, MO as of March 31, 2024, were US$1,073,723, representing personal loans from VG Zenith (a subsidiary) for Mr. Mo's personal investment. These were unsecured, interest-free, without specific repayment terms or written agreement, and were fully repaid in cash on November 7, 2024.
• Amounts due to Mr. Ka Wai Victor, MO as of March 31, 2025, were US$139,968, representing operational expenses paid by Mr. Mo on behalf of VG Zenith. These advances are unsecured, interest-free, and without specific repayment terms or written agreements.
• Salary compensation paid by Operating Subsidiaries to Mr. Ka Wai Victor, MO: US$2,526,629 for FY2025 and US$563,863 for FY2024.
• Salary compensation paid by Operating Subsidiaries to Ms. Sum Lok, CHEUNG (Director and Chief Operating Officer, spouse of Mr. Mo): US$603,105 for FY2025 and US$236,689 for FY2024.

Stakeholder Impact

• Shareholders: New investors face immediate and substantial dilution. The concentrated ownership by AW Ocean Limited (96.53% voting power) means minority shareholders will have limited influence. The auditor's 'going concern' warning and significant decline in net income pose substantial risks to investment value. No dividends are planned, so returns depend solely on price appreciation.
• Employees: Increased headcount in operations and support, along with one-off discretionary bonuses for senior management, indicates growth in staffing and management compensation. Ongoing training programs aim to enhance staff expertise and service quality.
• Customers: The company's expansion plans, including new service centers and R&D into at-home devices, aim to broaden service offerings and enhance customer experience. High customer satisfaction rates suggest positive current impact.
• Suppliers: Continued reliance on third-party suppliers for treatment devices and products, without long-term agreements, could expose the company to supply chain risks, potentially affecting service delivery.
• Creditors: The working capital deficit and the auditor's 'going concern' warning indicate increased financial risk for current and potential creditors.

Next Steps

• Listing Ordinary Shares on the Nasdaq Capital Market under the symbol AVG.
• Developing and commercializing pain management treatment devices, with a prototype expected in early 2026 and market readiness by the end of 2026.
• Establishing a new service center in Hong Kong (Causeway Bay center opened in June 2025).
• Strategically expanding market coverage into selected global markets, including Singapore, Malaysia, Japan, South Korea, Canada, and the United States.
• Enhancing and upgrading the information technology system and infrastructure.
• Maintaining and enhancing the professional expertise of frontline staff through continuous training and recruitment.
• Developing and broadening the variety of treatment services and product offerings, including diversifying topical use and dietary supplement product lines.
• Establishing a specialized research and development department in the first quarter of 2025.

Key Dates

Recommendation

The company's financial health is concerning, marked by a 53% drop in net income and a persistent working capital deficit, leading its auditor to express 'substantial doubt' about its ability to continue as a going concern. While the IPO aims to raise capital, the underlying financial instability, coupled with significant operational risks (e.g., reliance on a single market, lack of product liability insurance, no long-term supplier contracts), and the controlling shareholder's dominant voting power, make this a high-risk investment. The immediate and substantial dilution for new investors further diminishes its attractiveness. A seasoned investor would likely view these factors as strong reasons to avoid or exit the investment.

Keywords

Pain Management, Health Services, Hong Kong, IPO, Nasdaq, Traditional Chinese Medicine, TCM, Energy-Based Treatment, Wellness, Healthcare, SEC Filing, F-1/A, ANEW HEALTH LIMITED, ANKH, RDS+